Table 3 Real-world effectiveness of palbociclib–summary of evidence available
References | Design | Follow-up | Setting | n | Results |
|---|---|---|---|---|---|
Torres et al. [27] | Retrospective multicentric cohort study | Median: 19.4 months | First line (palbo + AI) | 878 | Median PFS: 21.9 months (95%CI 20.1–28.2) |
Varella et al. [15] | Retrospective single-center cohort study | Median: 10.2 months | First line (palbo + AI) | 57 | Median PFS: 15.1 months (95%CI 12.3-NR) |
Taylor-Stokes et al. [18] | Retrospective multicentric cohort study | Mean: 9.9 months (SD 5.2) | First line (palbo + AI) | 360 | PFS at 12 months: 84.1% OS at 12 months: 95.1% |
Wilkie et al. [16] | Retrospective single-center cohort study | Not available | First line (palbo + AI) | 70 | Median PFS: 26.4 months (95%CI 19.7–33.2) |
Waller et al. [19] | Retrospective multicentric cohort study | Mean: 10 months (SD 4) | First line (palbo + AI) | 105 | PFS at 6 months: 94.0% OS at 6 months: 98.0% |
DeMichelle et al.[25] | Retrospective multicentric cohort study | Mean: 24.2 months (IQR, 14.2–34.9) | First line (palbo + AI) | 1430 | Median PFS: 20.0 months OS not reached |
Palumbo et al. [26] | Prospective multicentric cohort study | Mean: 24 months (range 6–32) | First line (palbo + AI) | 182 | Median PFS: 14.0 months Median OS: 25.0 months |